木香对非小细胞肺癌中吉非替尼耐药的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (707 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Saussurea costus and Indian costus combined with Gefitinib on the model of C. elegans which was resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), and to research the main effective active components. Methods Genotyped anthropogenic (LET-23::hEGFR-TK[T790M- L858R]) C. elegans mutant jgIs25 was used to ensure the effective inhibitory concentration of Saussurea costus and Indian costus. The effective active components were preliminarily determined by HPLC (Hypersil BDS C18 250 mm×4.6 mm, 5 μm, detection wavelength: 220 nm). Results There were significant differences in the vulva expression of C. elegans jgIs25, when the concentration of Indian costus was 100-750 μg/mL and Saussurea costus was 500-750 μg/mL (P ＜ 0.01). It was preliminarily speculated that the active monomers were costunolide and dehydrocostus lactone. Conclusion Radix Aucklandiae combined with Gefitinib can reverse EGFR-TKI resistance in non-small cell lung cancer. It can provide the basis for the follow-up clinical research.

Key words： Radix Aucklandiae Non-small cell lung cancer Epidermal growth factor receptor tyrosine kinase inhibitors C. elegans

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TONG Yanli1 HUANG Guan2 MEI Qinghua1 YANG Shuiyuan1

Cite this article:

TONG Yanli1 HUANG Guan2 MEI Qinghua1 YANG Shuiyuan1. Effect of Radix Aucklandiae on the resistance of Gefitinib in non-small cell lung cancer[J]. 中国医药导报, 2020, 17(22): 29-31,37.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I22/29

[1] Kumara A，Petri ET，Halmos B，et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer [J]. J Clin Oncol，2008，26（10）：1742-1751.
[2] Shiau CJ，Babwan JP，Santos GC，et al. Sample features associated with success rates in population-based EGFR mutation testing [J]. J Thorac Oncol，2014，9（7）：947-956.
[3] Yu HA，Arcila ME，Rekhtman N，et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR mutant lung cancers [J]. Clin Cancer Res，2013，9（8）：2240-2247.
[4] Jnne PA，Yang JC，Kim DW，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer [J]. N Engl J Med， 2015，372（18）：1689-1699.
[5] Goss G，Tsai CM，Shepherd FA，et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer（AURA2），a multicentre，open-label，single-arm phase 2 study [J]. Lancet Oncol，2016，17（12）：1643-1652.
[6] Mok TS，Wu YL，Ahn MJ，et al. Osimertinib or Platinum Pemetrexed in EGFR T790M Positive Lung Cancer [J]. N Engl J Med，2017，376（7）：629-640.
[7] Yang JC，Kim DW，Kim SW，et al. Osimertinib activity in patients（pts）with lepto meningeal（LM）disease from non-small cell lung cancer（NSCLC）：updated results from BLOOM a phaseⅠstudy [J]. J Clin Oncol，2016，34（15 suppl）：9002.
[8] Nie KK，Zou X，Geng CX，et al. AZD9291- induced acute interstitial lung disease [J]. Chin Med J，2016，129（12）：1507-1508.
[9] Ballard P，Yates JW，Yang Z，et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models，and Early Evidence of Clinical Brain Metastases Activity [J]. Clin Cancer Res，2016，22（20）：5130-5140.
[10] Remon J，Steuer CE，Ramalingam SS，et al. Osimertinib and other third-generation EGFR-TKI in EGFR-mutant NSCLC patients [J]. Ann Oncol，2018，29（suppl 1）：i20-i27.
[11] 盛琦，陈建，李菌.姜黄素逆转非小细胞肺癌吉非替尼耐药的研究[J].中国现代应用药学，2013，30（4）：360-364.
[12] 熊绍权，李亚玲，王淑美，等.EGFR-TKIs联合中药与单纯EGFR-TKIs治疗晚期非小细胞肺癌的队列研究[J]. 四川大学学报：医学版，2018，49（4）：566-569.
[13] 王一喆，胡雪君.β-榄香烯治疗晚期非小细胞肺癌的临床应用现状及研究进展[J].现代肿瘤医学，2018，26（10）：1643-1646.
[14] 王媛，刘莉，陆远，等.紫草素逆转埃克替尼对肺癌EGFR-TKI耐药及其机制的研究[J].现代生物医学进展，2016， 16（16）：3044-3047.
[15] 顾晓燕，汪洋，陈建，等.消癌平对非小细胞肺癌厄洛替尼耐药的逆转作用[J].药物与临床，2014，11（6）：30-34.
[16] 李新泽，李亚博.吉非替尼联合中药治疗局部晚期非小细胞肺癌疗效观察[J].现代中西医结合杂志，2017，26（18）：2028-2029.
[17] Hang Z，Hua C，Yuan R，et al. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug—resistance in vitro and in vivo [J]. Mol Biol Rep，2012，39（4）：4971-4979.
[18] Wang YC，Wu DW，Wu TC，et al. Dioscin overcome TKI resistance in EGFR- mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression [J]. Int J Biol Sci，2018，14（1）：47-56.
[19] Chieh C，Paul WS. C. elegans vulval development as a model system to study the cancer biology of EGFR signaling [J]. Cancer and Meta Rev，1999，18（2）：203-213.
[20] 吴蒙，姚开泰.木香内酯抑制肺癌细胞H460生长的机制研究[J].医学研究生学报，2017，30（9）：932-936.